Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Cross-reactivity00:42

Cross-reactivity

31.1K
Overview
31.1K
Hybridoma Technology01:31

Hybridoma Technology

14.7K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Analysis of monoclonal antibodies against the malaria invasion complex protein RIPR reveals the structural basis for synergistic antibody protection.

Immunity·2026
Same author

ANARCII enables alignment-free antigen receptor numbering using a generalised language model.

Communications biology·2026
Same author

The good, the bad, and the stable: Reference genes for preclinical biodistribution studies.

Molecular therapy. Advances·2026
Same author

High Concordance of Total Antibody and Transduction Inhibition Assays Enables Replacement of Cell-Based Antibody Testing for Preexisting Anti-AAV Immunity in Cynomolgus Monkey.

The AAPS journal·2026
Same author

iNOS modulates inflammatory responses in an NO-independent manner through direct interaction with IRG1 in mitochondria.

Nature metabolism·2026
Same author

Rational discovery of therapeutic PAK1 allosteric activators.

Cell·2026

相关实验视频

Updated: Jun 28, 2025

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood
13:14

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Published on: February 6, 2018

10.4K

通过机器学习从抗体序列数据中预测多特异性.

Szabolcs Éliás1, Clemens Wrzodek1, Charlotte M Deane2

  • 1Roche Pharma Research and Early Development Informatics, Roche Innovation Center Munich, Penzberg, Germany.

Frontiers in bioinformatics
|April 23, 2024
PubMed
概括

科学家们开发了一种机器学习模型,以预测多特异性抗体,这可能会导致副作用. 该工具通过早期识别多特异性,有助于开发更安全,更有效的治疗抗体.

关键词:
抗体是一种抗体.深度学习是一种深度学习.免疫系统的曲目.免疫球蛋白是一种免疫球蛋白.机器学习是机器学习.神经网络的神经网络的神经网络多特异性的多特异性.治疗性抗体治疗性抗体.

更多相关视频

Identification of Mouse and Human Antibody Repertoires by Next-Generation Sequencing
08:51

Identification of Mouse and Human Antibody Repertoires by Next-Generation Sequencing

Published on: March 15, 2019

12.4K
Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
11:10

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

14.1K

相关实验视频

Last Updated: Jun 28, 2025

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood
13:14

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Published on: February 6, 2018

10.4K
Identification of Mouse and Human Antibody Repertoires by Next-Generation Sequencing
08:51

Identification of Mouse and Human Antibody Repertoires by Next-Generation Sequencing

Published on: March 15, 2019

12.4K
Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
11:10

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

14.1K

科学领域:

  • 生物技术是生物技术.
  • 免疫学 免疫学 免疫学
  • 计算生物学 计算生物学

背景情况:

  • 由于其特异性,抗体对生物药物至关重要.
  • 治疗抗体必须是安全和有效的.
  • 多特异性抗体可以结合意想不到的标,造成不良影响并降低疗效.

研究的目的:

  • 开发一种针对抗体多特异性的预测模型.
  • 识别影响多特异性的特征.
  • 帮助开发更安全的治疗抗体.

主要方法:

  • 使用抗体重链可变区域序列创建了一个基于神经网络的模型.
  • 开发了一种策略,以丰富针对特定或多特异结合的抗体.
  • 为模型培训和验证生成并使用大型测序数据集.

主要成果:

  • 成功开发了一种机器学习模型来预测抗体多特异性.
  • 确定了影响多特异性的关键物理化学特征.
  • 展示了一种丰富抗体的方法,使其具有所需的结合性质.

结论:

  • 神经网络模型为预测抗体多特异性提供了一种新的方法.
  • 了解多特异性可以改善治疗抗体设计.
  • 这种机器学习方法可能会提高基于抗体的药物的安全性和有效性.